Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Targeting mTOR signaling can prevent the progression of FSGS
Stefan Zschiedrich
, Tillmann Bork
, Wei Liang
, Nicola Wanner
, Kristina Eulenbruch
, Stefan Munder
, Björn Hartleben
, Oliver Kretz
, Simon Gerber
, Matias Simons
, Amandine Viau
, Martine Burtin
,
Changli Wei
,
Jochen Reiser
, Nadja Herbach
, Maria Pia Rastaldi
, Clemens D. Cohen
, Pierre Louis Tharaux
, Fabiola Terzi
, Gerd Walz
Markus Gödel, Tobias B. Huber
Show 2 others
Show less
Research output
:
Contribution to journal
›
Article
›
peer-review
74
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting mTOR signaling can prevent the progression of FSGS'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Mammalian Target of Rapamycin (mTOR)
100%
Mammalian Target of Rapamycin Signaling
100%
Raptor
25%
Podocyte
25%
Podocyte Injury
25%
Human Studies
12%
Pharmacologic
12%
Metabolic
12%
Clinical Trials
12%
Pharmacological Inhibitors
12%
Genetic Disease
12%
Reactive Oxygen Species Production
12%
Rapamycin
12%
MTOR Inhibitor
12%
Disease Model
12%
Oxidative Phosphorylation (OXPHOS)
12%
Prototypic
12%
Disease Progression
12%
Kidney Function
12%
Remission
12%
Cellular Stress
12%
Titration
12%
Kidney Disease
12%
Glomerular Disease
12%
Cellular Energy Metabolism
12%
Conflicting Results
12%
Reduced Rate
12%
Glomerulus
12%
Anaerobic Glycolysis
12%
Dedifferentiation
12%
Mammalian Target of Rapamycin Inhibition
12%
Glomerulosclerosis
12%
Treatment Rationale
12%
Immortalized Podocytes
12%
Pharmacology, Toxicology and Pharmaceutical Science
Mammalian Target of Rapamycin
100%
Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone)
66%
Clinical Trial
16%
Human Study
16%
Reactive Oxygen Metabolite
16%
Kidney Disease
16%
Rapamycin
16%
Mammalian Target of Rapamycin Inhibitor
16%
Disease Exacerbation
16%
Deterioration
16%
Remission
16%
Disease Model
16%
Mammalian Target of Rapamycin Complex 1
16%
Glomerulopathy
16%
Glomerulosclerosis
16%
Diseases
16%
Immunology and Microbiology
Sirolimus
100%
Podocyte
50%
Allele
25%
Cell Energy
12%
Energy Metabolism
12%
Oxidative Phosphorylation
12%
Low Drug Dose
12%
Kidney Function
12%
Mammalian Target of Rapamycin Complex 1
12%
Glomerulus
12%
Cell Stress
12%
Anaerobic Glycolysis
12%
Cell Dedifferentiation
12%